Teva Pharmaceutical Industries Limited (TEVA) PT Set at $17.00 by Cantor Fitzgerald

Cornelia Mascio
Settembre 22, 2017

Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a "sell" rating to a "hold" rating and set a $32.27 price target for the company in a research report on Wednesday, June 28th.

Several research analysts have issued reports on the company.

Michael Price increased its stake in Teva Pharmaceutical Industries Ltd. (TEVA) by 48.41% based on its latest 2016Q4 regulatory filing with the SEC. The rating was downgraded by Credit Suisse on Tuesday, September 5 to "Sell".

Teva Pharmaceutical Industries (NYSE:TEVA) was boosted by equities researchers at BidaskClub from a "strong sell" recommendation to a "sell" recommendation in a research note released to investors and clients on early Wed, Sep 13th. Royal Bank Of Canada reiterated an "outperform" recommendation and fixed a $37.00 price objective (down from $38.00) on stocks of Teva Pharmaceutical Industries in a study note on early Mon, Jul 17th. Five investment analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The firm has "Hold" rating by Argus Research given on Tuesday, February 28.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 0.23% during midday trading on Thursday, reaching $17.15. The company had a trading volume of 15,443,089 shares. Price Michael F bought 227,200 shares as the company's stock declined 15.11% while stock markets rallied. The firm has a 50 day moving average of $18.13 and a 200-day moving average of $28.20. Teva Pharmaceutical Industries Limited has a 12-month low of $15.22 and a 12-month high of $51.51.

Teva Pharmaceutical Industries Limited (TEVA) opened at 17.11 on Thursday. Traders acquired 20,895 put options on the stock.

Teva Pharmaceutical Industries (NYSE:TEVA) previously released its fiscal periodic earnings information on Early Thur, Aug 3rd.

Yet another important factor while evaluating a good buy/sell decision for Teva Pharmaceutical Industries Limited (TEVA) is its Earnings per Share or EPS. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business's revenue was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.25 EPS. The company reported $0.99 EPS for the quarter, missing analysts' consensus estimates of $1.06 by ($0.07).

ILLEGAL ACTIVITY NOTICE: This story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another publication, it was copied illegally and republished in violation of global trademark and copyright law. Teva Pharmaceutical Industries Limited's revenue was up 12.9% compared to the same quarter a year ago.

Several other research firms also recently commented on TEVA. Comerica Bank lifted its stake in Teva Pharmaceutical Industries Limited by 21.3% during the first quarter. The stock has "Market Perform" rating by Wells Fargo on Monday, January 9. Capital Research Global Investors lifted its stake in Teva Pharmaceutical Industries Limited by 13.8% in the 2nd quarter. Bronfman E.L. Rothschild L.P. increased its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% in the second quarter. FMR has an ownership of 42,844,979 stocks of the firms shares valued $1,423,310,000 following purchasing an extra 6,115,853 shares through out the previous quarter, Northern Cross upped its stake in Teva Pharmaceutical Industries by 14.0% through out the 2nd period.

A number of large investors have recently modified their holdings of the stock.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE